Inhibitor Therapeutics director granted 50K shares

Vasisht Niraj reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 06/01/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vasisht Niraj reported acquisition or exercise transactions in this Form 4 filing.

Inhibitor Therapeutics, Inc. director Niraj Vasisht received a grant of 50,000 shares of restricted common stock as compensation under the company’s 2025 Equity Incentive Plan. The grant was recorded at a price of $0.00 per share, and his directly held common stock position increased to 200,000 shares following this award.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Vasisht Niraj

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	50,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 200,000 shares (Direct)

Footnotes (1)

1. F1. Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan.

Key Figures

Restricted stock grant: 50,000 shares Grant price: $0.00 per share Post-transaction holdings: 200,000 shares

3 metrics

Restricted stock grant 50,000 shares Common Stock, granted as compensation on 2026-05-05

Grant price $0.00 per share Recorded value for restricted common stock grant

Post-transaction holdings 200,000 shares Common Stock directly held after the grant

Key Terms

restricted common stock, 2025 Equity Incentive Plan, Grant, award, or other acquisition

3 terms

restricted common stock financial

"Represents restricted common stock issued to the Reporting Person as compensation"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

2025 Equity Incentive Plan financial

"as compensation pursuant to the Issuer's 2025 Equity Incentive Plan"

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did INTI director Niraj Vasisht report?

Director Niraj Vasisht reported receiving 50,000 shares of restricted common stock in Inhibitor Therapeutics. The shares were issued as compensation, not bought on the open market, and are tied to the company’s 2025 Equity Incentive Plan.

Was the INTI insider transaction a market purchase or a grant?

The INTI insider transaction was a grant, not a market purchase. Niraj Vasisht received 50,000 restricted common shares as compensation under the 2025 Equity Incentive Plan, with a recorded price of $0.00 per share.

How many INTI shares does Niraj Vasisht hold after this Form 4?

After this Form 4 transaction, Niraj Vasisht directly holds 200,000 shares of Inhibitor Therapeutics common stock. This total includes the newly granted 50,000 restricted shares issued as compensation pursuant to the 2025 Equity Incentive Plan.

What plan governed the restricted stock grant to the INTI director?

The restricted stock grant to the INTI director was made under Inhibitor Therapeutics’ 2025 Equity Incentive Plan. The filing specifies that the 50,000 restricted common shares issued to Niraj Vasisht represented compensation pursuant to this equity incentive program.

Does the INTI Form 4 indicate any derivative or option exercises?

The INTI Form 4 does not indicate any derivative or option exercises. It reports only a single non-derivative transaction: a grant of 50,000 restricted common shares to director Niraj Vasisht as compensation, with no derivative positions shown in the derivative summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vasisht Niraj

(Last) (First) (Middle)

C/O INHIBITOR THERAPUTICS, INC.,

3014 WEST PALMIRA AVE SUITE 302

(Street)

TAMPA FLORIDA 33629

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibitor Therapeutics, Inc. [ INTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		A		50,000(1)	A	$0	200,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan.

	/s/ Niraj Vasisht	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)